Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 6/20 | 0.39 |
| ▸ | DRD5 | P21918 | 6/20 | 0.39 |
| ▸ | DRD4 | P21917 | 6/20 | 0.39 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | DRD3 | P35462 | 5/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285299 | 0.74 | CYP1A2 (0.45) | KDM4EGRM5 | |
| SCHEMBL9963883 | 0.73 | ADORA3 (0.35) | DRD1GRM5 | |
| SCHEMBL12797127 | 0.72 | NOTUM (0.43) | DRD1DRD5MAPTSMN1; SMN2HPGD | |
| SCHEMBL12622660 | 0.70 | GRM5 (0.40) | KDM4EGRM5 | |
| SCHEMBL12797113 | 0.70 | GABRP (0.47) | KDM4EMAPTSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL9963886 | 0.70 | MME (0.38) | DRD1PKMGRM5 | |
| SCHEMBL10202352 | 0.66 | DRD4 (0.45) | DRD4KDM4ENPC1MAPTRAB9A | |
| SCHEMBL12299471 | 0.65 | PDE10A (0.39) | GRM5 | |
| SCHEMBL19820948 | 0.65 | GRM5 (0.33) | DRD1DRD5DRD4DRD2DRD3 | |
| SCHEMBL10202788 | 0.65 | CYP2A6 (0.39) | DRD1DRD5DRD4NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-19 | — | — | US | disclosed |
| US-9771337-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170088526-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-30 | — | — | US | disclosed |
| US-9499487-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-20120309724-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309724-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | DRD1 1527/4885DRD5 1694/4885DRD4 912/4885 |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | DRD1 1527/4885DRD5 1694/4885DRD4 912/4885 |
| US-20170088526-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | DRD1 1527/4885DRD5 1694/4885DRD4 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.